Brazikumab

Brazikumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL23
Clinical data
Other namesMEDI2070
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6410H9830N1718O2016S50
Molar mass144820.16 g·mol−1

Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease.[1][2] that targets IL-23.[3]

This drug was developed by MedImmune.

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association
  2. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
  3. ^ Hanžel J, D'Haens GR (April 2020). "Anti-interleukin-23 agents for the treatment of ulcerative colitis". Expert Opinion on Biological Therapy. 20 (4): 399–406. doi:10.1080/14712598.2020.1697227. PMID 31760827.